BGNE

BeiGene, Ltd. (NASDAQ:ONC) is a global biotechnology company founded in 2010 and headquartered in Camana Bay, Cayman Islands. The company has established itself as a leading oncology-focused pharmaceutical enterprise, specializing in the discovery, development, and commercialization of innovative cancer treatments. BeiGene went public in 2016 and has since grown into a significant player in the global oncology market, with operations spanning the United States, China, Europe, and other international markets. The company recently announced plans to redomicile to Switzerland and rebrand as BeOne Medicines, reflecting its evolution from a primarily China-focused biotech to a truly global pharmaceutical company.